- Report
- August 2025
- 180 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- March 2025
- 150 Pages
Global
From €3410EUR$3,850USD£2,951GBP
€4296EUR$4,850USD£3,717GBP
- Report
- July 2025
- 250 Pages
Global
From €3977EUR$4,490USD£3,441GBP
- Report
- August 2025
- 377 Pages
Global
From €5182EUR$5,850USD£4,483GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1772EUR$2,000USD£1,533GBP
- Report
- January 2025
- 152 Pages
Global
From €2569EUR$2,900USD£2,223GBP
- Report
- April 2025
- 211 Pages
Global
From €2214EUR$2,500USD£1,916GBP
- Report
- August 2025
- 50 Pages
Global
From €2347EUR$2,650USD£2,031GBP
- Report
- August 2025
- 183 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- August 2025
- 180 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- August 2025
- 180 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- August 2025
- 383 Pages
Global
From €5182EUR$5,850USD£4,483GBP
- Report
- August 2025
- 459 Pages
Global
From €5182EUR$5,850USD£4,483GBP
- Report
- August 2025
- 395 Pages
Global
From €5182EUR$5,850USD£4,483GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1107EUR$1,250USD£958GBP
- Report
- January 2025
- 201 Pages
Global
From €2214EUR$2,500USD£1,916GBP
- Report
- December 2024
- 130 Pages
Global
From €2119EUR$2,392USD£1,833GBP
€2648EUR$2,990USD£2,291GBP
- Report
- August 2025
- 198 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- August 2025
- 194 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP
- Report
- August 2025
- 180 Pages
Global
From €3140EUR$3,545USD£2,717GBP
€3489EUR$3,939USD£3,019GBP

Cannabidiol (CBD) is a cannabinoid found in the Cannabis sativa plant. It is a non-psychoactive compound that has been studied for its potential therapeutic effects on the central nervous system (CNS). CBD has been found to have anti-inflammatory, antioxidant, and neuroprotective properties, and has been studied for its potential to treat a variety of neurological disorders, including epilepsy, anxiety, depression, and Parkinson's disease.
CBD is increasingly being used as an alternative to traditional CNS drugs, such as benzodiazepines and opioids. It is being studied for its potential to reduce the side effects of traditional medications, as well as its potential to treat a variety of neurological conditions.
The CBD market is growing rapidly, with a variety of products available, including oils, tinctures, edibles, and topical creams. Companies in the market include Charlotte's Web, Elixinol, and Endoca. Show Less Read more